Autoimmunity and Cancer—Two Sides of the Same Coin
Open Access
- 13 May 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 793234
Abstract
Autoimmune disease results from the immune response against self-antigens, while cancer develops when the immune system does not respond to malignant cells. Thus, for years, autoimmunity and cancer have been considered as two separate fields of research that do not have a lot in common. However, the discovery of immune checkpoints and the development of anti-cancer drugs targeting PD-1 (programmed cell death receptor 1) and CTLA-4 (cytotoxic T lymphocyte antigen 4) pathways proved that studying autoimmune diseases can be extremely helpful in the development of novel anti-cancer drugs. Therefore, autoimmunity and cancer seem to be just two sides of the same coin. In the current review, we broadly discuss how various regulatory cell populations, effector molecules, genetic predisposition, and environmental factors contribute to the loss of self-tolerance in autoimmunity or tolerance induction to cancer. With the current paper, we also aim to convince the readers that the pathways involved in cancer and autoimmune disease development consist of similar molecular players working in opposite directions. Therefore, a deep understanding of the two sides of immune tolerance is crucial for the proper designing of novel and selective immunotherapies.Keywords
Funding Information
- Narodowe Centrum Nauki (DEC-2011/01/D/NZ3/00262)
- Fundacja na rzecz Nauki Polskiej (MAB/2017/3)
- Gdański Uniwersytet Medyczny (ST-49)
- European Social Fund Plus (POWR.03.05.00-00-z082/18)
This publication has 367 references indexed in Scilit:
- Molecular Mimicry as a Mechanism of Autoimmune DiseaseClinical Reviews in Allergy & Immunology, 2011
- Genetics of the HLA Region in the Prediction of Type 1 DiabetesCurrent Diabetes Reports, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Interleukin-6 in bone metastasis and cancer progressionEuropean Journal of Cancer, 2010
- Inflammation and EMT: an alliance towards organ fibrosis and cancer progressionEMBO Molecular Medicine, 2009
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Molecular Antagonism and Plasticity of Regulatory and Inflammatory T Cell ProgramsImmunity, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- CD4+CD25+ regulatory T cells in rheumatoid arthritis: Differences in the presence, phenotype, and function between peripheral blood and synovial fluidArthritis & Rheumatism, 2004